A clinical trial to study magnesium sulphate in patient with pregnancy with high blood pressure

Randomised control trial for comparison of 12hours v/s 24 hours post-partum maintenance therapy of magnesium sulphate in severe pre- eclampsia and eclampsia patients’ - NIL

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/066966

Enrollment

198

Registered

2024-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 1- Obstetrics

Interventions

Intervention1: pregnant women with severe pre eclampsia and eclampsia: magnesium sulphate drug 4gm intavenous followed by maintenace dose 1gm per hour intavenous for 12 hours in severe pre eclampsia a

Eligibility

Inclusion criteria

Inclusion criteria: Women with severe pre-eclapsia and eclampsia admitted to OBGY department PSMC,karmsad

Exclusion criteria

Exclusion criteria: Status eclampicus Renal compromise Patient recieve other anti convulsant except magnesium sulphate

Design outcomes

Primary

Measure	Time frame
To determine the recurrence of convlsions in patients receiving 12hrs/24hrs maintenance dose of magnesium sulphateTimepoint: To determine the recurrence of convlsions in patients receiving 12hrs/24hrs maintenance dose of magnesium sulphate	—

Secondary

Measure	Time frame
maternal morbidity Respiratory failure,ICU admission,total hospital stay,hospital acquired infection. NEonatal outcome first contact with mother,NICU admission,APGAR AT 5mins,neonatal morbidityTimepoint: baseline	—

Countries

India

Contacts

Public Contactsunita pandya

PSMC karmsad anand

docsunitapandya@gmail.com8094488479

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026